At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
human rhinovirus +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans
In Brief
A Phase 2 clinical trial evaluating human rhinovirus and no intervention for Healthy Volunteers. Completed, enrolled 46 participants across 1 site.
Detailed Summary
The primary objective of this study is to assess the relationship between rhinovirus specific T-cell immunity and the human host response to primary rhinovirus challenge and subsequent secondary challenge with either homologous or heterologous rhinovirus serotypes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartSep 2017
Primary CompletionMay 2020
TodayJul 2026
First PostedJun 10, 2016
Enrollment StartSep 25, 2017
Primary CompletionMay 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 10.1 years ago
Interventions
human rhinovirusbiological
human rhinovirus
no interventionother
4 volunteers were not re-challenged and did not participate in the second challenge